NCT00003451View on ClinicalTrials.gov

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 1998

Primary Completion Date

December 31, 2001

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesPrecancerous ConditionUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

recombinant interferon alfa

BIOLOGICAL

recombinant interleukin-12

Trial Locations (1)

43210

Arthur G. James Cancer Hospital - Ohio State University, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003451 - Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter